The restricted expression profile of this target in normal tissues, the high prevalence in different types of hematologic cancers and the observed preclinical activity support the clinical development of SAIL-targeted ADCs. The gene discussed is C16orf54; the disease is hematopoietic and lymphoid cell neoplasm.